Search

Displaying results 2791 - 2800 of 4598 in total
  1. Drug

    Asenapine

    go.drugbank.com/drugs/DB06216
    ApprovedInvestigational

    Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with

  2. Drug

    Formaldehyde

    go.drugbank.com/drugs/DB03843
    ApprovedVet approved

    A highly reactive aldehyde gas formed by oxidation or incomplete combustion of hydrocarbons.

  3. Drug

    Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10801
    ApprovedInvestigational

    Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria

  4. Drug

    Trichloroacetate

    go.drugbank.com/drugs/DB11152
    ApprovedInvestigational

    Trichloroacetate, or trichloroacetic acid, is a strong acid prepared by the reaction of chlorine with acetic acid in the presence of a suitable catalyst.

  5. Drug

    Fenbufen

    go.drugbank.com/drugs/DB08981
    Approved

    Fenbufen acts by preventing cyclooxygenase from producing prostaglandins which can cause inflammation.

  6. Drug

    Trestolone

    go.drugbank.com/drugs/DB05830
    Investigational

    Trestolone (7α-methyl-19-nortestosterone) is a synthetic androgen developed by the Population Council as a potential candidate drug for use in hormonal male contraceptive methods.

  7. Drug

    Talimogene laherparepvec

    go.drugbank.com/drugs/DB13896
    ApprovedInvestigational

    It was approved by the FDA in 2015 under the market name Imlygic. In general, talimogene laherparepvec has been modified so that it can infect and multiply inside melanoma cells [L2221].

  8. Drug

    Larazotide

    go.drugbank.com/drugs/DB05645
    Investigational

    An octapeptide inhibitor of paracellular permeability whose structure is derived from a protein (zonula occludens toxin) secreted by Vibrio cholerae for treatment of Coeliac disease.

  9. Drug

    Sacubitril

    go.drugbank.com/drugs/DB09292
    ApprovedInvestigational

    It was approved by the FDA after being given the status of priority review for on July 7, 2015.

  10. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.